New Opioids: Industry Stakeholders Support US FDA's Desire For Active Comparator Data

Although only a few companies commented on the FDA's draft guidance on the benefit/risk assessment of new opioids, they cut against conventional wisdom by supporting the agency's desire to see active comparator data.